产品
编 号：F031676
分子式：C54H69N11O10S2
分子量：1096.32
分子式：C54H69N11O10S2
分子量：1096.32
产品类型
规格
价格
是否有货
结构图
CAS No: 108736-35-2
产品详情
生物活性：
Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome.
体内研究：
Lanreotide (2.5-10mg/kg; s.c.; daily for 5 days) results in tumor growth inhibition.Animal Model:Male nude mice, 8 weeks old and 20–25?g in body weight (GH3 tumor-bearing nude mice)
Dosage:2.5, 5, 10?mg/kg
Administration:Subcutaneous; daily for 5 days
Result:Produced tumor growth inhibition.
体外研究：
Lanreotide (BIM 23014) (100? nM; 0-48 h) enhanced radiation-induced apoptosis.Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC50 is 57?nM.Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro.
Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome.
体内研究：
Lanreotide (2.5-10mg/kg; s.c.; daily for 5 days) results in tumor growth inhibition.Animal Model:Male nude mice, 8 weeks old and 20–25?g in body weight (GH3 tumor-bearing nude mice)
Dosage:2.5, 5, 10?mg/kg
Administration:Subcutaneous; daily for 5 days
Result:Produced tumor growth inhibition.
体外研究：
Lanreotide (BIM 23014) (100? nM; 0-48 h) enhanced radiation-induced apoptosis.Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC50 is 57?nM.Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备